SanBio Company Limited
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company's research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction inj… Read more
SanBio Company Limited (SNBIF) - Total Liabilities
Latest total liabilities as of July 2025: $1.93 Billion USD
Based on the latest financial reports, SanBio Company Limited (SNBIF) has total liabilities worth $1.93 Billion USD as of July 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SanBio Company Limited - Total Liabilities Trend (2014–2025)
This chart illustrates how SanBio Company Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
SanBio Company Limited Competitors by Total Liabilities
The table below lists competitors of SanBio Company Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sk Gas
KO:018670
|
Korea | ₩4.69 Trillion |
|
Hootech Inc.
SHE:301026
|
China | CN¥2.51 Billion |
|
RWS Holdings plc
PINK:RWSPF
|
USA | $277.70 Million |
|
Hengxin Mobile Business
SHE:300081
|
China | CN¥977.43 Million |
|
AngioDynamics Inc
NASDAQ:ANGO
|
USA | $93.35 Million |
|
Natural Grocers by Vitamin Cottage Inc
NYSE:NGVC
|
USA | $448.55 Million |
|
Tremor International Ltd
PINK:TTTPF
|
USA | $309.66 Million |
|
Intrum AB (publ)
PINK:ITJTY
|
USA | $60.52 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down SanBio Company Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SanBio Company Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SanBio Company Limited (2014–2025)
The table below shows the annual total liabilities of SanBio Company Limited from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | $1.68 Billion | -25.30% |
| 2024-01-31 | $2.25 Billion | -13.81% |
| 2023-01-31 | $2.62 Billion | -24.73% |
| 2022-01-31 | $3.48 Billion | -30.40% |
| 2021-01-31 | $4.99 Billion | +6.82% |
| 2020-01-31 | $4.68 Billion | -7.73% |
| 2019-01-31 | $5.07 Billion | +16.69% |
| 2018-01-31 | $4.34 Billion | +155.86% |
| 2017-01-31 | $1.70 Billion | -10.97% |
| 2016-01-31 | $1.91 Billion | +3.42% |
| 2015-01-31 | $1.84 Billion | -24.37% |
| 2014-01-31 | $2.44 Billion | -- |